

Recombinant Human IL-17A (carrier-free)

Catalog # / Size: 570502 / 10 µg
570504 / 25 µg
570506 / 100 µg
570508 / 500 µg

Source: Human IL-17A, amino acids Ile20-Ala155 (Accession # NM_002190) was expressed in *E. coli*.

Molecular Mass: The 137 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 15,666 Da. This protein exists as a disulfide-linked homodimer. The DTT-reduced protein migrates at approximately 16kDa by SDS-PAGE. The non-reduced protein migrates as a homodimer, at approximately 28kDa by SDS-PAGE.

Purity: Purity is >98%, as determined by Coomassie stained SDS-PAGE.


Endotoxin Level: Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.

Activity: The ED₅₀ is 2 - 4 ng/ml, corresponding to a specific activity 5 - 2.5 x 10⁵ units/mg, as determined by a dose dependent stimulation of normal human dermal fibroblasts production of IL-6.

Preparation: 10-100µg sizes are bottled at 200µg/ml. 500µg and larger sizes are bottled at the concentration indicated on the vial.

Formulation: 0.22 µm filtered protein solution is in 10mM NaH₂PO₄, 300mM NaCl, pH 7.2.

Storage: Unopened vial can be stored at -20°C for six months or at -70°C for one year. For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10µg/mL in buffer containing carrier protein such as 1% BSA or HSA or 10% FBS. For long term storage, aliquot into polypropylene vials and store in a manual defrost freezer. **Avoid repeated freeze/thaw cycles.**



Induction of IL-6 in human dermal fibroblast by IL-17A.

Applications:

Applications: Bioassay

Description: IL-17A was initially identified from a subtracted cDNA library between closely related murine lymphoid cells and called CTLA-8, and share 58% homology with an open reading frame of the T-lymphotropic Herpesvirus Samirii virus (viral IL-17) (5). IL-17A belongs to a family of cytokines, which has five members; designated IL-17A-F. IL-17 is expressed by a unique lineage of CD4 T cells (Th17) that develop in response to IL-23, in particular under conditions in which Th1 and Th2 development are suppressed. IL-17A shares the greatest homology (55%) with IL-17F. Both IL-17A and IL-17F are produced by Th17 cells. IL-17A and IL-17F can either exist as IL-17A homodimers and IL-17F homodimers or as IL-17A-IL-17F heterodimers (6). IL-17 is a key mediator of autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and asthma, and plays a role in host defense (7).

Antigen References:

1. Yu J, *et al. Front Biosci* 13:170-177 2008.
2. Toy D, *et al. J. Immunol.* 177:36-39 2006.
3. Benghiat FS, *et al. Transplant Rev* 23:11-18 2009.
4. Honorati MC, *et al. Rheumatology* 40:522-527 2001.
5. Rouvier E, *et al. J. Immunol.* 150:5445-5456 1993.
6. Liang SC, *et al. J. Immunol.* 179:7791-7799 2007.
7. Ouyang W, *et al. Immunity* 28:454-467 2008.



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.



*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.